These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8160684)

  • 1. Bayesian and threshold probabilities in therapeutic drug monitoring: when can serum drug concentrations alter clinical decisions?
    Schumacher GE; Barr JT
    Am J Hosp Pharm; 1994 Feb; 51(3):321-7. PubMed ID: 8160684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian approaches in pharmacokinetic decision making.
    Schumacher GE; Barr JT
    Clin Pharm; 1984; 3(5):525-30. PubMed ID: 6488735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using population-based serum drug concentration cutoff values to predict toxicity: test performance and limitations compared with Bayesian interpretation.
    Schumacher GE; Barr JT
    Clin Pharm; 1990 Oct; 9(10):788-96. PubMed ID: 2242660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying decision analysis in therapeutic drug monitoring: using decision trees to interpret serum theophylline concentrations.
    Schumacher GE; Barr JT
    Clin Pharm; 1986 Apr; 5(4):325-33. PubMed ID: 3709081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring and pharmacokinetic dose prediction methods.
    Oellerich M
    Wien Klin Wochenschr Suppl; 1992; 191():12-5. PubMed ID: 1509745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical inferences and decisions--II. Decision trees, receiver operator curves and subjective probability.
    Aspinall P; Hill AR
    Ophthalmic Physiol Opt; 1984; 4(1):31-8. PubMed ID: 6709368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The threshold approach to clinical decision making.
    Pauker SG; Kassirer JP
    N Engl J Med; 1980 May; 302(20):1109-17. PubMed ID: 7366635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recent aspects of monitoring the dosage of aminoglycosides and vancomycin].
    Cheymol G; Poirier JM
    Bull Acad Natl Med; 1998; 182(2):285-97; discussion 297-8. PubMed ID: 9648344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling, adaptive control, and optimal drug therapy.
    Jelliffe RW; Schumitzky A
    Med Prog Technol; 1990 May; 16(1-2):95-110. PubMed ID: 2138702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Individualized monitoring of the therapy with gentamycin using pharmacokinetic methods. Which method to choose?].
    Carvalho A; Fonseca C; Falcão F; Pereira TA; Freitas O; Parrinha A; Costa M; Rodrigues MJ; Ceia F; Luís AS
    Acta Med Port; 1996; 9(7-9):187-95. PubMed ID: 9005695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probabilistic reporting of EUS-FNA cytology: Toward improved communication and better clinical decisions.
    Eltoum IA; Chen VK; Chhieng DC; Jhala D; Jhala NC; Crowe R; Varadarajulu S; Eloubeidi MA
    Cancer; 2006 Apr; 108(2):93-101. PubMed ID: 16444743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage.
    Bondareva IB; Jelliffe RW; Sokolov AV; Tischenkova IF
    J Clin Pharm Ther; 2004 Apr; 29(2):105-20. PubMed ID: 15068399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting.
    Proost JH
    Int J Clin Pharmacol Ther; 1995 Oct; 33(10):531-6. PubMed ID: 8574501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applying decision analysis in therapeutic drug monitoring: using receiver-operating characteristic curves in comparative evaluations.
    Barr JT; Schumacher GE
    Clin Pharm; 1986 Mar; 5(3):239-46. PubMed ID: 3514086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The decision theory of paternity disputes: optimization considerations applied to multilocus DNA fingerprinting.
    Krawczak M; Schmidtke J
    J Forensic Sci; 1992 Nov; 37(6):1525-33. PubMed ID: 1453166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sharing the diagnostic process in the clinical teaching environment: a case study.
    Cuello-García C
    J Contin Educ Health Prof; 2005; 25(4):231-9. PubMed ID: 16365896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic drug monitoring with the help of serum concentration measurements. How are the analytic results distributed in a population?].
    Skomedal T; Osnes JB; Johannessen SI; Lund PK; Aass H
    Tidsskr Nor Laegeforen; 1993 Aug; 113(18):2242-6. PubMed ID: 8362387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication monitoring in the elderly.
    Fowler JB
    Clin Lab Sci; 1995; 8(1):34-8. PubMed ID: 10150465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating uncertainty into medical decision making: an approach to unexpected test results.
    Bianchi MT; Alexander BM; Cash SS
    Med Decis Making; 2009; 29(1):116-24. PubMed ID: 18812583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.